Endocrine Abstracts

Introduction: ACROCOMB, a retrospective Spanish Multicenter study, evaluated the efficacy and safety of lanreotide (LAN) combined with cabergoline (CAB), or pegvisomant in patients with acromegaly.Methods: patients treated with LAN+CAB at 44 Spanish Endocrinology Departments were included.Results: 33% male patients, median age: 50.4 years. Mean time from diagnosis: 5.9±6.9 years. Tumour size at diagnosis: 21.9 mm. 83% of patie...

The impairment of cognitive function found in patients treated for pituitary adenomas has been associated with the effects of conventional radiotherapy (CR). Our aim was to compare the results of an examination of verbal memory function in acromegalic patients treated with transsphenoidal surgery (TS) alone to those obtained from patients treated with TS followed by CR. We retrospectively compared these two outcome groups and carried out a story recall test that included free ...

Neurocognitive dysfunction has been described in patients following pituitary radiotherapy. However, the relative contributions of other variables such as hormone-deficiency states and surgery is still unknown. Our aim was to compare the results of an examination of executive function in acromegalic patients treated with transsphenoidal surgery (TS) alone to those obtained from patients treated with TS followed by conventional radiotherapy (CR) using a two-field technique. We ...

Introduction: ACROCOMB is a retrospective Spanish Multicenter study, designed to evaluate the efficacy (extent of tumour control) and safety of lanreotide (LAN) treatment combined with pegvisomant (PEG) or cabergoline in acromegalic patients with monotherapy failure.Methods: patients with acromegaly treated with LAN+PEG (45% of ACROCOMB patients) at 44 Spanish Endocrinology Departments were analysed.Results: 40% of patients were ma...